2nd January 2026, Friday

TechPharus

Latest Posts

HealthTech News

  • AI detects stomach cancer risk in remote communities from upper endoscopic images
    on January 2, 2026 at 5:13 pm

    In many regions, doctors practice in settings with limited medical resources. Advanced tests, specialist support, and expert guidance for complex decisions are often unavailable. Under these circumstances, accurate automated systems, especially AI, can help close the gap between limited resources and clinical needs.

  • AI model predicts B cell reactivity to neoantigens for improved cancer vaccines
    on January 2, 2026 at 4:24 pm

    Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity that “remembers” cancer, effectively preventing recurrence. KAIST’s research team has developed an AI-based personalized cancer vaccine design technology that makes this possible and optimizes anticancer effects for each individual.

  • Potential biomarker linked to multiple sclerosis progression and brain inflammation
    on January 2, 2026 at 4:12 pm

    A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

  • Australia’s red and yellow beach flags can be dangerously confusing. Is it time to change them?
    on January 2, 2026 at 3:58 pm

    Every summer in Australia, millions of people head to the beach, and every year, thousands are rescued by lifeguards or Surf Life Savers and even surfers or other bystanders. Tragically, many people lose their lives on our coasts.

  • High-dose risankizumab trial tests staying power against psoriasis
    on January 2, 2026 at 3:38 pm

    Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that paired higher-than-approved doses of risankizumab with extended follow-up and found high early skin clearance alongside reduced lesional tissue-resident memory T cells at Week 52.